Fatty Liver Clinical Trial
Official title:
Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong: Natural History and Development of Liver Complications
Verified date | June 2008 |
Source | Hospital Authority, Hong Kong |
Contact | n/a |
Is FDA regulated | No |
Health authority | Hong Kong: Ethics Committee |
Study type | Observational |
The true incidence and prevalence of NAFLD in Hong Kong has not been determined. The natural
history of NAFLD is not well defined partly because of differences in the exclusion limit of
alcohol and the required histological criteria between studies. NAFLD is previously believed
to be a benign non-progressive condition, but it has since been determined that a subset of
patients can progress to cirrhosis and even hepatocellular carcinoma.
In fact in a recent histological review of NAFLD, fibrosis or liver cirrhosis was present in
15-50% of patients at index liver biopsy. The presence of obesity or type 2 diabetes
mellitus are the strongest predictors of fibrosis. These same risk factors are also more
common in patients with cryptogenic cirrhosis. Further evidence of the link between
diabetes, obesity and NAFLD are mainly from the field of liver transplantation. In patients
who underwent liver transplantation for cryptogenic liver cirrhosis, NAFLD recuured in a
quarter of the hepatic allografts. The patients with recurrent NAFLD were more likely to be
diabetic and had a higher body mass index (BMI) at the time of recurrent NAFLD. This
suggests that NAFLD may have a significant role in the pathogenesis of crytogenic cirrhosis.
Although NAFLD was initially described as a slowly progressive disease, there are emerging
data which shows that it can progress rapidly. Liver failure has even been described in
patients with NAFLD after bariatric surgery, and a recent report described 5 cases of
subacute liver failure in obese middle aged females with NAFLD related cirrhosis. NAFLD can
also affect the progression of other diseases as well. Hepatic steatosis related to visceral
obesity is a major independent risk factor for fibrogenesis related to chronic HCV
hepatitis.
However, the prevalence of NAFLD and its interaction with chronic HBV, if any, is uncertain.
This study aims to determine the prevalence of NAFLD in patients with unknown cause of
hepatitis and to determine the histological fibrosis and inflammation in chronic HBV
patients with NAFLD.
Status | Active, not recruiting |
Enrollment | 600 |
Est. completion date | December 2007 |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - 18-80 years old - Gender: male and female Exclusion Criteria: - HBV patients and fatty liver HCV HIV |
N/A
Country | Name | City | State |
---|---|---|---|
China | Department of Medicine, Queen Mary Hospital | Hong Kong | |
China | Department of Pathology, Princess Margaret Hospital | Hong Kong | |
China | Department of Pathology, Queen Elizabeth Hospital | Hong Kong | |
China | Department of Pathology, Queen Mary Hospital | Hong Kong | |
China | Department of Pathology, Tuen Mun Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Hospital Authority, Hong Kong | The University of Hong Kong |
China,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT06051669 -
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
|
||
Not yet recruiting |
NCT05984745 -
Effect of CoQ10 on the Outcome of MAFLD Patients
|
Phase 2 | |
Completed |
NCT02565446 -
Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram
|
N/A | |
Not yet recruiting |
NCT01694342 -
Telomere Parameters in Patients With Nonalcoholic Fatty Liver
|
N/A | |
Completed |
NCT01464801 -
Resveratrol in Patients With Non-alcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT01992809 -
Omega 3 Supplementation in Fatty Liver
|
Phase 3 | |
Completed |
NCT00063635 -
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
|
Phase 3 | |
Completed |
NCT00244569 -
Development of a Breath Test for Monitoring Patients With Liver Disease
|
Phase 3 | |
Recruiting |
NCT03972319 -
Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study
|
Early Phase 1 | |
Completed |
NCT03141008 -
Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
|
||
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Recruiting |
NCT05125757 -
Lifestyle Modification in Psoriatic Patients With Fatty Liver
|
N/A | |
Recruiting |
NCT05370053 -
The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology
|
N/A | |
Recruiting |
NCT04371042 -
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
|
||
Completed |
NCT04004273 -
Diabetes, Exercise and Liver Fat (DELIVER)
|
N/A | |
Completed |
NCT02520609 -
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
|
||
Recruiting |
NCT02265276 -
A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
|
Phase 3 | |
Completed |
NCT02347007 -
Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
|
N/A | |
Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 |